{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:54:54Z","timestamp":1776862494666,"version":"3.51.2"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4998,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.exphem.2008.04.017","type":"journal-article","created":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T06:51:59Z","timestamp":1215759119000},"page":"1244-1253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFR\u03b1"],"prefix":"10.1016","volume":"36","author":[{"given":"Christian","family":"Baumgartner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoline V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Ferenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gruze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily L.","family":"Remsing Rix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiryn L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puchit","family":"Samorapoompichit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried F.","family":"Pickl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Esterbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sillaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Superti-Furga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2008.04.017_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-97-1-78","article-title":"NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations","volume":"97","author":"Fauci","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.exphem.2008.04.017_bib2","first-page":"2","article-title":"Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome","volume":"95","author":"Bain","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2008.04.017_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0165-4608(98)00099-5","article-title":"Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality","volume":"107","author":"Oliver","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.exphem.2008.04.017_bib4","series-title":"World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues","first-page":"29","volume":"Vol. 1","author":"Bain","year":"2001"},{"key":"10.1016\/j.exphem.2008.04.017_bib5","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000085559","article-title":"Molecular classification and pathogenesis of eosinophilic disorders: 2005 update","volume":"114","author":"Gotlib","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.exphem.2008.04.017_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000085562","article-title":"Modern diagnosis and treatment of primary eosinophilia","volume":"114","author":"Tefferi","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.exphem.2008.04.017_bib8","first-page":"177","article-title":"Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"125","author":"Cools","year":"2006","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.exphem.2008.04.017_bib9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2008.04.017_bib10","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1073\/pnas.0601192103","article-title":"Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent","volume":"103","author":"Stover","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2008.04.017_bib11","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.04.017_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semcancer.2004.03.002","article-title":"Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate","volume":"14","author":"Coutr\u00e9","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.exphem.2008.04.017_bib14","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2003.10.006","article-title":"Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2008.04.017_bib16","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1l1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2008.04.017_bib18","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-005-1084-7","article-title":"Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature","volume":"85","author":"M\u00fcller","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2008.04.017_bib20","first-page":"236","article-title":"Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome","volume":"89","author":"Martinelli","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2008.04.017_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2007.06628.x","article-title":"Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia","volume":"138","author":"Curtis","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2008.04.017_bib22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drup.2005.04.005","article-title":"Resistance to tyrosine kinase inhibitors: calling on extra forces","volume":"8","author":"Cools","year":"2005","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.exphem.2008.04.017_bib24","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1 PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib25","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.leukres.2006.03.012","article-title":"Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells","volume":"30","author":"Verstovsek","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2008.04.017_bib26","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1182\/blood-2003-07-2479","article-title":"The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA positive chronic eosinophilic leukemia","volume":"103","author":"Cools","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00062752-200401000-00008","article-title":"The FIP1L1 PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"11","author":"Cools","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2008.04.017_bib28","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.04.017_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.exphem.2008.04.017_bib30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib31","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2008.04.017_bib32","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.04.017_bib33","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1439-0264.2002.00398.x","article-title":"Morphological and biochemical aspects of apoptosis, oncosis and necrosis","volume":"31","author":"Van Cruchten","year":"2002","journal-title":"Anat Histol Embryol"},{"key":"10.1016\/j.exphem.2008.04.017_bib35","first-page":"1945","article-title":"Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays","volume":"53","author":"Gorczyca","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.04.017_bib36","first-page":"1945","article-title":"Detection of strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidal transferase and nick translation assays","volume":"53","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.04.017_bib37","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","article-title":"STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells","volume":"5","author":"Sillaber","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib39","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib40","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib41","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias","volume":"109","author":"Weisberg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib42","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2008.04.017_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nm0107-15a","article-title":"In reply to \u201cCardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"13","author":"Rosti","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2008.04.017_bib44","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/eji.1830210525","article-title":"Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interleukin 2 receptor subunit","volume":"21","author":"Plumas","year":"1991","journal-title":"Eur J Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2008.04.017_bib46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000237723","article-title":"Identification of surface molecules on eosinophils and lymphocytes in blood from patients with eosinophilia","volume":"114","author":"Enokihara","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.exphem.2008.04.017_bib47","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","article-title":"The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils","volume":"111","author":"Kneidinger","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.017_bib48","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.exphem.2007.06.005","article-title":"Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells","volume":"35","author":"Gleixner","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2008.04.017_bib49","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08002063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08002063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:25:34Z","timestamp":1759566334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X08002063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0301472X08002063"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2008.04.017","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFR\u03b1","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2008.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}